4RY Stock Overview
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Akeso, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$7.25 |
52 Week High | HK$8.65 |
52 Week Low | HK$3.60 |
Beta | 0.51 |
11 Month Change | 3.57% |
3 Month Change | 61.11% |
1 Year Change | 53.60% |
33 Year Change | 51.67% |
5 Year Change | n/a |
Change since IPO | 121.27% |
Recent News & Updates
Recent updates
Shareholder Returns
4RY | DE Biotechs | DE Market | |
---|---|---|---|
7D | -16.2% | -0.3% | 0.8% |
1Y | 53.6% | -12.1% | 14.0% |
Return vs Industry: 4RY exceeded the German Biotechs industry which returned -12.1% over the past year.
Return vs Market: 4RY exceeded the German Market which returned 14% over the past year.
Price Volatility
4RY volatility | |
---|---|
4RY Average Weekly Movement | 11.0% |
Biotechs Industry Average Movement | 6.4% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4RY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4RY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 2,815 | Michelle Xia | www.akesobio.com |
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.
Akeso, Inc. Fundamentals Summary
4RY fundamental statistics | |
---|---|
Market cap | €6.57b |
Earnings (TTM) | -€95.16m |
Revenue (TTM) | €242.54m |
27.1x
P/S Ratio-69.1x
P/E RatioIs 4RY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4RY income statement (TTM) | |
---|---|
Revenue | CN¥1.87b |
Cost of Revenue | CN¥146.05m |
Gross Profit | CN¥1.73b |
Other Expenses | CN¥2.46b |
Earnings | -CN¥735.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.85 |
Gross Margin | 92.21% |
Net Profit Margin | -39.24% |
Debt/Equity Ratio | 64.2% |
How did 4RY perform over the long term?
See historical performance and comparison